Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that using an oral contraceptive with bicalutamide significantly reduced hirsutism in women with PCOS compared to an oral contraceptive alone, although it increased total cholesterol and LDL levels.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

This meta-analysis reported that dienogest and combined oral contraceptives had comparable efficacy and tolerability for endometriosis treatment, with therapeutic choice suggested to be based on patient preference and clinical history.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

This study reports that among young women, combined oral contraceptives containing chlormadinone, among others, are associated with an increased risk of venous thromboembolism compared to those containing levonorgestrel with low ethinylestradiol.

This study assessed vitamin E and a combined oral contraceptive's impact on continuous light-induced PCOS in female rats, finding they reduced testosterone levels and modified oxidative stress, suggesting benefits via melatonin-related pathways.

This study suggests that using combined oral contraceptives does not increase hair glucocorticoid levels, but hair treatments should be considered as a confounder in stress biomarker assessments.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

This study found that a low dose of flutamide, both alone and combined with an oral contraceptive, effectively reduced hirsutism in women, with the combination showing more lasting effects post-treatment.

This study reported that both drospirenone and chlormadinone acetate oral contraceptives had similar beneficial effects on clinical, metabolic, and hormonal parameters in women with polycystic ovary syndrome over six months.

This study found that feeding norethindrone acetate to albino rats over two years caused various dose-related health effects, such as growth retardation and liver changes, but did not increase overall tumor incidence.

This review discusses the increased risk of venous thromboembolism associated with combined hormonal contraceptives, particularly noting higher risks with certain progestins like desogestrel, gestodene, and cyproterone acetate, but reports no new clinical findings.

This review discusses the effectiveness and mechanisms of combined oral contraceptives in treating acne vulgaris but reports no new clinical results; the authors highlight their antiandrogenic effects for managing acne and related endocrine disorders.

This review discusses the role of contraceptives in dermatology, particularly for acne treatment and managing patients on teratogens, but reports no new clinical results.

This review examines the role of hormones in acne pathogenesis, the use of hormonal therapies for treatment, and the importance of contraceptive counseling during isotretinoin therapy, but reports no new clinical results.

This review explores contraceptive options for women with polycystic ovary syndrome, emphasizing the need for tailored choices based on individual clinical, hormonal, and metabolic profiles, but reports no new clinical findings.

Hormonal contraceptives are effective for teens but require careful consideration of side effects and individual health.

This review discusses the diagnosis and treatment of hyperandrogenism in women, emphasizing that cyproterone acetate is effective for severe hirsutism, though it reports no new clinical findings.

This article reviews the effects of combined oral contraceptives on skin conditions and suggests prescribing guidelines for women with acne, as it reports no new clinical results.

This review discusses the use of different types of oral contraceptive pills and highlights their effectiveness, potential side effects, and contraindications without presenting new clinical data.

This review discusses contraceptive options for adolescent girls, highlighting potential recommendations and contraindications, and reports no new clinical findings.

This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo.

In this study, treatment with flutamide combined with a low-dose oral contraceptive significantly improved hirsutism in women with polycystic ovarian disease who did not respond to oral contraceptive treatment alone.

This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results.

This review discusses the symptoms, diagnosis, and current treatment recommendations for polycystic ovary syndrome, noting that many women may remain undiagnosed and at risk for complications.

This review summarizes hair growth aspects, treatment options, and management strategies for hirsutism in women with polycystic ovary syndrome, without presenting new clinical findings.

This article reviews the hormonal pathogenesis and treatment strategies for acne vulgaris, particularly in women with severe or treatment-resistant cases, associating it with hormonal imbalances and hyperandrogenism.

This review examines androgen status in male and female obesity and its influence on the metabolic syndrome, but reports no new clinical results.